AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- Researchers review the safety and efficacy of trivalent inactivated influenza vaccine in young children in a recent issue of the Pediatric Infectious Disease Journal.
"Increasing use of influenza vaccine in children is expected as this important virus becomes more widely recognized as a major cause of morbidity in young children. Clinicians and third party payers must consider the implications of national vaccine use recommendations, with their current focus on young children, on their practices and on the community at large.
"Two influenza vaccines are available in the United States, an inactivated, trivalent intramuscular formulation (TIV) which is approved for use among children greater than or equal to6 months of age; and a live, attenuated intranasal trivalent preparation (LAIV) indicated for healthy persons 5 to 49 years of age," scientists in the United States report.
"This review summarizes available data regarding the safety and efficacy of TIV, in comparison with LAIV, with particular attention to children
Zangwill and Belshe published their review in the Pediatric Infectious Disease Journal (Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. ...